Abstract
Introduction During the 2022 mpox outbreak, the province of Quebec, Canada prioritized first doses for pre-exposure vaccination of people at high mpox risk, delaying second doses due to limited supply. We estimated single-dose mpox vaccine effectiveness (VE) adjusting for virus exposure risk based only on surrogate indicators available within administrative databases (e.g. clinical record of sexually transmitted infections), or supplemented by self-reported risk factor information (e.g. sexual contacts).
Methods We conducted a test-negative case-control study between June 19 and September 24, 2022. Information from administrative databases was supplemented by a questionnaire collecting self-reported risk factors specific to the three-week period before testing. Two study populations were assessed: all within the administrative databases (All-Admin) and the subset completing the questionnaire (Sub-Quest). Logistic regression models were adjusted for age, calendar-time and exposure-risk, the latter based on administrative indicators only (All-Admin and Sub-Quest populations) or supplemented by questionnaire information (Sub-Quest population).
Results There were 532 All-Admin participants, of which 199 (37%) belonged to Sub-Quest. With exposure-risk adjustment based only on administrative indicators, single-dose mpox VE among All-Admin and Sub-Quest populations was similar at 35% (95%CI:-2-59) and 30% (95%CI:-38-64), respectively. With adjustment supplemented by questionnaire information, Sub-Quest VE increased to 65% (95%CI:1-87). Protection against severe outcomes was higher (VE=82%; 95%CI:-50-98) but with overlapping confidence intervals.
Conclusions One vaccine dose reduced mpox risk by about two-thirds when adjustment incorporated self-reported risk factors, but by only one-third when adjustment relied solely upon administrative indicators. Inadequate adjustment for exposure risk may substantially under-estimate mpox VE.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Ministry of Health and Social Services.DT is supported by a research career award from the Fonds de recherche du Québec - Santé.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics commmittee of CHU de Québec - Université Laval gaved ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
When adjusting for differential exposure risk, one vaccine dose reduced the mpox risk by about two-thirds using self-reported risk factors, but by only one-third using surrogate indicators available within administrative databases. Inadequate adjustment for exposure risk under-estimates MVA-BN vaccine effectiveness.
Abbreviations: All-Admin, participants meeting eligibility criteria and using administrative data only; CI, confidence interval; gbMSM, gay, bisexual, and other men who have sex with men; GBTQ, gay, bisexual, trans, queer; HIV, human immunodeficiency virus; IQR, interquartile range; NA, not applicable; NAT, nucleic acid test; PNA, prefers not to answer; PrEP, pre-exposure prophylaxis; QPHL, Quebec Public Health Laboratory; STI, sexually transmitted infection; Sub-Quest; subset of All-Admin participants who completed the questionnaire; VE, vaccine effectiveness.
Data Availability
Data produced in the present study are available upon request.
